Circulating Tumour DNA Analysis for Early Detection of Lung Cancer: a Systematic Review

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2024 Aug 9

PMID 39118954

Authors

W K Jacky Lam

Jinyue Bai

Mary-Jane L Ma

Y T Tommy Cheung

Peiyong Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Circulating tumor DNA (ctDNA) analysis has been applied in cancer diagnostics including lung cancer. Specifically for the early detection purpose, various modalities of ctDNA analysis have demonstrated their potentials. Such analyses have showed diverse performance across different studies.

Methods: We performed a systematic review of original studies published before 1 January 2023. Studies that evaluated ctDNA alone and in combination with other biomarkers for early detection of lung cancer were included.

Results: The systematic review analysis included 56 original studies that were aimed for early detection of lung cancer. There were 39 studies for lung cancer only and 17 for pan-cancer early detection. Cancer and control cases included were heterogenous across studies. Different molecular features of ctDNA have been evaluated, including 7 studies on cell-free DNA concentration, 17 on mutation, 29 on methylation, 5 on hydroxymethylation and 8 on fragmentation patterns. Among these 56 studies, 17 have utilised different combinations of the above-mentioned ctDNA features and/or circulation protein markers. For all the modalities, lower sensitivities were reported for the detection of early-stage cancer.

Conclusions: The systematic review suggested the clinical utility of ctDNA analysis for early detection of lung cancer, alone or in combination with other biomarkers. Future validation with standardised testing protocols would help integration into clinical care.

Citing Articles

Predictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: a systematic review and meta-analysis.

Juang Y, Ang L, Seow W Sci Rep. 2025; 15(1):4259.

PMID: 40038330 PMC: 11880538. DOI: 10.1038/s41598-024-83875-6.

References

Zhou M, Hou P, Yan C, Chen L, Li K, Wang Y . Cell-free DNA 5-hydroxymethylcytosine profiles of long non-coding RNA genes enable early detection and progression monitoring of human cancers. Clin Epigenetics. 2021; 13(1):197. PMC: 8543867. DOI: 10.1186/s13148-021-01183-6. View

Markou A, Londra D, Tserpeli V, Kollias I, Tsaroucha E, Vamvakaris I . DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection. Clin Epigenetics. 2022; 14(1):61. PMC: 9092693. DOI: 10.1186/s13148-022-01283-x. View

Jonas D, Reuland D, Reddy S, Nagle M, Clark S, Weber R . Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021; 325(10):971-987. DOI: 10.1001/jama.2021.0377. View

Song C, Yin S, Ma L, Wheeler A, Chen Y, Zhang Y . 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Res. 2017; 27(10):1231-1242. PMC: 5630676. DOI: 10.1038/cr.2017.106. View

Ris F, Hellan M, Douissard J, Nieva J, Triponez F, Woo Y . Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGEN): Early Clinical Results. Cancers (Basel). 2021; 13(16). PMC: 8392437. DOI: 10.3390/cancers13164104. View

Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T . Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021; 5(6):586-599. DOI: 10.1038/s41551-021-00746-5. View

Chen K, Lou F, Yang F, Zhang J, Ye H, Chen W . Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing. Sci Rep. 2016; 6:31985. PMC: 4995492. DOI: 10.1038/srep31985. View

Meddeb R, Pisareva E, Thierry A . Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clin Chem. 2019; 65(5):623-633. DOI: 10.1373/clinchem.2018.298323. View

Lo Y, Chan K, Sun H, Chen E, Jiang P, Lun F . Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med. 2010; 2(61):61ra91. DOI: 10.1126/scitranslmed.3001720. View

10.

Nikolaev S, Lemmens L, Koessler T, Blouin J, Nouspikel T . Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory. Anal Biochem. 2017; 542:34-39. DOI: 10.1016/j.ab.2017.11.004. View

11.

Jiang P, Chan C, Chan K, Cheng S, Wong J, Wong V . Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015; 112(11):E1317-25. PMC: 4372002. DOI: 10.1073/pnas.1500076112. View

12.

Jiang P, Sun K, Peng W, Cheng S, Ni M, Yeung P . Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. Cancer Discov. 2020; 10(5):664-673. DOI: 10.1158/2159-8290.CD-19-0622. View

13.

Krasic J, Abramovic I, Vrtaric A, Nikolac Gabaj N, Kralik-Oguic S, Bojanac A . Impact of Preanalytical and Analytical Methods on Cell-Free DNA Diagnostics. Front Cell Dev Biol. 2021; 9:686149. PMC: 8451956. DOI: 10.3389/fcell.2021.686149. View

14.

Klein E, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D . Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32(9):1167-1177. DOI: 10.1016/j.annonc.2021.05.806. View

15.

Singh R . Next-Generation Sequencing in High-Sensitive Detection of Mutations in Tumors: Challenges, Advances, and Applications. J Mol Diagn. 2020; 22(8):994-1007. DOI: 10.1016/j.jmoldx.2020.04.213. View

16.

Vrba L, Oshiro M, Kim S, Garland L, Placencia C, Mahadevan D . DNA methylation biomarkers discovered detect cancer in liquid biopsies from non-small cell lung cancer patients. Epigenetics. 2019; 15(4):419-430. PMC: 7153541. DOI: 10.1080/15592294.2019.1695333. View

17.

Liang W, Zhao Y, Huang W, Gao Y, Xu W, Tao J . Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019; 9(7):2056-2070. PMC: 6485294. DOI: 10.7150/thno.28119. View

18.

Leng S, Zheng J, Jin Y, Zhang H, Zhu Y, Wu J . Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis. Clin Chim Acta. 2017; 477:160-165. DOI: 10.1016/j.cca.2017.11.003. View

19.

Bao H, Wang Z, Ma X, Guo W, Zhang X, Tang W . Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection. Mol Cancer. 2022; 21(1):129. PMC: 9188251. DOI: 10.1186/s12943-022-01594-w. View

20.

Agrawal L, Engel K, Greytak S, Moore H . Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Semin Cancer Biol. 2017; 52(Pt 2):26-38. PMC: 6004232. DOI: 10.1016/j.semcancer.2017.12.008. View